{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:07Z","timestamp":1790409247791,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":1781,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1111\/ajt.14584","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T06:45:34Z","timestamp":1514875534000},"page":"3-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"special_numbering":"S3","title":["Antibody-mediated rejection: New approaches in prevention and management"],"prefix":"10.1016","volume":"18","author":[{"given":"R.A.","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Loupy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.14584_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/TP.0000000000000959","article-title":"The challenge of acute antibody-mediated rejection in kidney transplantation","volume":"100","author":"Chehade","year":"2016","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.smim.2011.08.021","article-title":"Humoral immunity and antibody-mediated rejection in solid organ transplantation","volume":"23","author":"Montgomery","year":"2011","journal-title":"Semin Immunol."},{"issue":"8","key":"10.1111\/ajt.14584_bib3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.14584_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ajt.12982","article-title":"Quantifying renal allograft loss following early antibody-mediated rejection","volume":"15","author":"Orandi","year":"2015","journal-title":"Am J Transplant."},{"issue":"13","key":"10.1111\/ajt.14584_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.294.13.1655","article-title":"Clinical results from transplanting incompatible live kidney donor\/recipient pairs using kidney paired donation","volume":"294","author":"Montgomery","year":"2005","journal-title":"JAMA."},{"issue":"15","key":"10.1111\/ajt.14584_bib6","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.293.15.1883","article-title":"Kidney paired donation and optimizing the use of live donor organs","volume":"293","author":"Segev","year":"2005","journal-title":"JAMA."},{"issue":"3","key":"10.1111\/ajt.14584_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1600-6143.2009.03001.x","article-title":"Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols","volume":"10","author":"Montgomery","year":"2010","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14584_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000129260.86766.67","article-title":"The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome","volume":"78","author":"Claas","year":"2004","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol."},{"key":"10.1111\/ajt.14584_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria: An addition to the Banff \u201897 classification of renal allograft rejection","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: Updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrneph.2012.212","article-title":"The role of complement in antibody-mediated rejection in kidney transplantation","volume":"8","author":"Stegall","year":"2012","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"10.1111\/ajt.14584_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/TP.0000000000000203","article-title":"Determinants of C1q binding in the single antigen bead assay","volume":"98","author":"Schaub","year":"2014","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.14584_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ajt.14015","article-title":"Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival","volume":"17","author":"Wiebe","year":"2017","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib15","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.4049\/jimmunol.1501686","article-title":"The complement system and antibody-mediated transplant rejection","volume":"195","author":"Stites","year":"2015","journal-title":"J Immunol."},{"key":"10.1111\/ajt.14584_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.14584_bib17","doi-asserted-by":"crossref","first-page":"193724","DOI":"10.1155\/2012\/193724","article-title":"Antibody-mediated rejection in kidney transplantation: A review","volume":"2012","author":"Puttarajappa","year":"2012","journal-title":"J Transplant."},{"issue":"6","key":"10.1111\/ajt.14584_bib18","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/ajt.14161","article-title":"The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss","volume":"17","author":"Schinstock","year":"2017","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14584_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 Kidney Meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant."},{"issue":"10","key":"10.1111\/ajt.14584_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/01.TP.0000090868.88895.E0","article-title":"Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients","volume":"76","author":"Zachary","year":"2003","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOT.0b013e32835d4daf","article-title":"Pathology of C4d-negative antibody-mediated rejection in renal allografts","volume":"18","author":"Haas","year":"2013","journal-title":"Curr Opin Organ Transplant."},{"issue":"1","key":"10.1111\/ajt.14584_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.2014.166","article-title":"A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection","volume":"87","author":"Sapir-Pichhadze","year":"2015","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.14584_bib24","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/j.1600-6143.2009.02761.x","article-title":"Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining","volume":"9","author":"Sis","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib25","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2009.02813.x","article-title":"Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies","volume":"9","author":"Loupy","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","article-title":"Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)","volume":"11","author":"Loupy","year":"2011","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ajt.13434","article-title":"Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation","volume":"16","author":"Orandi","year":"2016","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14584_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00129039-200406000-00012","article-title":"Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: Comparison to frozen tissue immunofluorescence","volume":"12","author":"Chantranuwat","year":"2004","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"2","key":"10.1111\/ajt.14584_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.healun.2010.08.020","article-title":"Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients","volume":"30","author":"Chin","year":"2011","journal-title":"J Heart Lung Transplant."},{"issue":"8","key":"10.1111\/ajt.14584_bib30","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/j.1600-6143.2009.02701.x","article-title":"Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations","volume":"9","author":"Kraus","year":"2009","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.14584_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/TP.0b013e3182052be8","article-title":"Significance of peritubular capillary, glomerular, and arteriolar C4d staining patterns in paraffin sections of early kidney transplant biopsies","volume":"91","author":"Kiki\u0107","year":"2011","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.14584_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/TP.0000000000001195","article-title":"Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study","volume":"101","author":"Eskandary","year":"2017","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(12)61265-3","article-title":"Antibody-mediated vascular rejection of kidney allografts: A population-based study","volume":"381","author":"Lefaucheur","year":"2013","journal-title":"Lancet."},{"issue":"6","key":"10.1111\/ajt.14584_bib34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00007890-200009270-00006","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","journal-title":"Transplantation."},{"issue":"1","key":"10.1111\/ajt.14584_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-6143.2006.01613.x","article-title":"Immunoadsorption in severe C4d-positive acute kidney allograft rejection: A randomized controlled trial","volume":"7","author":"B\u00f6hmig","year":"2007","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients: A systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant."},{"issue":"Suppl 3","key":"10.1111\/ajt.14584_bib38","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ctr.12491","article-title":"Treatment of antibody-mediated rejection in renal transplant patients: A clinical practice survey","volume":"29","author":"Burton","year":"2015","journal-title":"Clin Transplant."},{"issue":"5","key":"10.1111\/ajt.14584_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00007890-198305000-00006","article-title":"Plasma exchange in acute renal allograft rejection. A controlled trial","volume":"35","author":"Allen","year":"1983","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1172\/JCI114483","article-title":"Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies","volume":"85","author":"Dietrich","year":"1990","journal-title":"J Clin Invest."},{"key":"10.1111\/ajt.14584_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig)","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev."},{"issue":"12","key":"10.1111\/ajt.14584_bib43","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.14584_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/TP.0b013e318253f7b6","article-title":"Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients","volume":"94","author":"Alachkar","year":"2012","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.14584_bib45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14584_bib46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1111\/ajt.14584_bib47","series-title":"Rituxan [package insert]","year":"2016"},{"key":"10.1111\/ajt.14584_bib48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/phar.1426","article-title":"Antibody-mediated rejection in kidney transplantation: A review of the pathology, diagnosis, and treatment options","volume":"34","author":"Kim","year":"2014","journal-title":"Pharmacotherapy."},{"key":"10.1111\/ajt.14584_bib49","first-page":"51","article-title":"A systematic review and meta-analysis of rituximab in antibody-mediated renal allograft rejection","volume":"2","author":"Hychko","year":"2011","journal-title":"Int J Organ Transplant Med."},{"key":"10.1111\/ajt.14584_bib50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/TP.0000000000000362","article-title":"A systematic review of the use of rituximab for desensitization in renal transplantation","volume":"98","author":"Macklin","year":"2014","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib51","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant."},{"issue":"13","key":"10.1111\/ajt.14584_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5414\/CNP88FX21","article-title":"Treatment of antibody-mediated rejection of kidney grafts with bortezomib and\/or rituximab compared to standard regimen: Experience of Slovene National Center","volume":"88","author":"Oblak","year":"2017","journal-title":"Clin Nephrol."},{"key":"10.1111\/ajt.14584_bib53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.14584_bib54","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/TP.0b013e31827be3c1","article-title":"Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA","volume":"95","author":"Zachary","year":"2013","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.14584_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ki.2014.261","article-title":"A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation","volume":"87","author":"Jackson","year":"2015","journal-title":"Kidney Int."},{"issue":"Suppl 1","key":"10.1111\/ajt.14584_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cei.12508","article-title":"Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20","volume":"178","author":"Vo","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"10.1111\/ajt.14584_bib57","series-title":"Velcade [package insert]","year":"2015"},{"key":"10.1111\/ajt.14584_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"1","author":"Perry","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib59","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2016070727","article-title":"Humoral compensation after bortezomib treatment of allosensitized recipients","volume":"28","author":"Kwun","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.14584_bib60","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","article-title":"32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody","volume":"101","author":"Moreno Gonzales","year":"2017","journal-title":"Transplantation."},{"issue":"12","key":"10.1111\/ajt.14584_bib61","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib62","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/ndt\/gfr465","article-title":"Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection","volume":"27","author":"Waiser","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"10.1111\/ajt.14584_bib63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.TP.0000442503.85766.91","article-title":"Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies","volume":"97","author":"Gupta","year":"2014","journal-title":"Transplantation."},{"issue":"6","key":"10.1111\/ajt.14584_bib64","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/TP.0000000000000132","article-title":"Differential effect of bortezomib on HLA class I and class II antibody","volume":"98","author":"Philogene","year":"2014","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib65","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-IL-6 receptor monoclonal) as a potential treatment for chronic antibody mediated rejection and transplant glomerulopathy in HLA sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14584_bib66","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","article-title":"A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib67","series-title":"Soliris [package insert]","year":"2016"},{"issue":"12","key":"10.1111\/ajt.14584_bib68","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant."},{"issue":"18","key":"10.1111\/ajt.14584_bib69","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1111\/ajt.14584_bib70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14584_bib71","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib73","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib74","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib75","series-title":"Alexion provides update on Phase 2 clinical trial with eculizumab in antibody mediated rejection (AMR) in living-donor kidney transplant recipients [press release]","year":"2015"},{"issue":"suppl 3","key":"10.1111\/ajt.14584_bib76","first-page":"3039","article-title":"Eculizumab in prevention of acute antibody-mediated rejection in sensitized deceased-donor kidney transplant recipients: 1-year outcomes [abstract]","volume":"15","author":"Glotz","year":"2015","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib77","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1600-6143.2006.01709.x","article-title":"The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection","volume":"7","author":"Locke","year":"2007","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14584_bib79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ajt.14001","article-title":"Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: A pilot randomized controlled trial","volume":"17","author":"Kulkarni","year":"2017","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib80","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/TP.0000000000000184","article-title":"Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts","volume":"98","author":"Burbach","year":"2014","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib81","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1111\/ajt.14584_bib82","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/13543784.15.9.1077","article-title":"The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema","volume":"15","author":"Levy","year":"2006","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1111\/ajt.14584_bib83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib84","series-title":"Berinert [package insert]","year":"2015"},{"key":"10.1111\/ajt.14584_bib85","series-title":"Cinryze [package insert]","year":"2014"},{"key":"10.1111\/ajt.14584_bib86","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 Inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: A pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib87","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody mediated rejection following kidney transplantation: Results of a randomized, double-blind, placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib88","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts","volume":"26","author":"Loupy","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"50","key":"10.1111\/ajt.14584_bib89","doi-asserted-by":"crossref","first-page":"17371","DOI":"10.1073\/pnas.0407965101","article-title":"Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG","volume":"101","author":"Wenig","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"12","key":"10.1111\/ajt.14584_bib90","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.4049\/jimmunol.1501929","article-title":"The bacterial enzyme ideS cleaves the IgG-type of B cell receptor (BCR), abolishes BCR-mediated cell signaling, and inhibits memory B cell activation","volume":"195","author":"J\u00e4rnum","year":"2015","journal-title":"J Immunol."},{"issue":"5","key":"10.1111\/ajt.14584_bib91","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1111\/ajt.14584_bib92","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.humimm.2011.07.001","article-title":"Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads","volume":"72","author":"Chen","year":"2011","journal-title":"Hum Immunol."},{"key":"10.1111\/ajt.14584_bib93","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/TP.0b013e318203fd26","article-title":"C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation","volume":"91","author":"Yabu","year":"2011","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.14584_bib95","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/TP.0000000000000672","article-title":"Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing","volume":"99","author":"Susal","year":"2015","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib96","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/TP.0000000000001012","article-title":"De novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury","volume":"100","author":"Yamamoto","year":"2016","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14584_bib97","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00467-016-3322-8","article-title":"Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients","volume":"31","author":"Fichtner","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"10.1111\/ajt.14584_bib98","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/ajt.13153","article-title":"Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation","volume":"15","author":"O\u2019Leary","year":"2015","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib99","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.healun.2012.09.021","article-title":"Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients","volume":"32","author":"Zeevi","year":"2013","journal-title":"J Heart Lung Transplant."},{"issue":"9","key":"10.1111\/ajt.14584_bib100","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: Comparison of MFI, C1q, and titer information","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14584_bib101","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-6143.2012.04291.x","article-title":"Five-year outcomes in living donor kidney transplants with a positive crossmatch","volume":"13","author":"Bentall","year":"2013","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib102","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ajt.12150","article-title":"Molecular diagnosis of antibody mediated rejection in human kidney transplants","volume":"13","author":"Sellar\u00e9s","year":"2013","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14584_bib103","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.12465","article-title":"Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM)","volume":"13","author":"Halloran","year":"2013","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14584_bib104","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/TP.0000000000001231","article-title":"Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: A cross-sectional analysis of pathological findings in allograft biopsies","volume":"101","author":"Philogene","year":"2017","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.14584_bib105","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2013121277","article-title":"Endothelial cell antibodies associated with novel targets and increased rejection","volume":"26","author":"Jackson","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1111\/ajt.14584_bib106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1681\/ASN.2014040378","article-title":"Through a glass darkly: Seeking clarity in preventing late kidney transplant failure","volume":"26","author":"Stegall","year":"2015","journal-title":"J Am Soc Nephrol."}],"updated-by":[{"DOI":"10.1111\/ajt.14751","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000}}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14584\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T10:22:20Z","timestamp":1674382940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522098410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":106,"alternative-id":["S1600613522098410"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14584","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-mediated rejection: New approaches in prevention and management","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}